Checkpoint Graham Number from 2010 to 2024

CKPT Stock  USD 4.28  0.18  4.39%   
Checkpoint Therapeutics Graham Number yearly trend continues to be comparatively stable with very little volatility. Graham Number will likely drop to 6.25 in 2024. From the period from 2010 to 2024, Checkpoint Therapeutics Graham Number quarterly data regression had r-value of (0.90) and coefficient of variation of  46.66. View All Fundamentals
 
Graham Number  
First Reported
2010-12-31
Previous Quarter
6.58235083
Current Value
6.25
Quarterly Volatility
16.7719244
 
Credit Downgrade
 
Yuan Drop
 
Covid
Check Checkpoint Therapeutics financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Checkpoint Therapeutics' main balance sheet or income statement drivers, such as Interest Income of 102.1 K, Depreciation And Amortization of 159.5 K or Interest Expense of 5.2 M, as well as many indicators such as Price To Sales Ratio of 438, Dividend Yield of 0.0 or Days Sales Outstanding of 168. Checkpoint financial statements analysis is a perfect complement when working with Checkpoint Therapeutics Valuation or Volatility modules.
  
Check out the analysis of Checkpoint Therapeutics Correlation against competitors.
For more information on how to buy Checkpoint Stock please use our How to Invest in Checkpoint Therapeutics guide.

Latest Checkpoint Therapeutics' Graham Number Growth Pattern

Below is the plot of the Graham Number of Checkpoint Therapeutics over the last few years. It is Checkpoint Therapeutics' Graham Number historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Checkpoint Therapeutics' overall financial position and show how it may be relating to other accounts over time.
Graham Number10 Years Trend
Slightly volatile
   Graham Number   
       Timeline  

Checkpoint Graham Number Regression Statistics

Arithmetic Mean35.95
Geometric Mean30.25
Coefficient Of Variation46.66
Mean Deviation14.17
Median38.73
Standard Deviation16.77
Sample Variance281.30
Range53.0576
R-Value(0.90)
Mean Square Error58.67
R-Squared0.81
Slope(3.37)
Total Sum of Squares3,938

Checkpoint Graham Number History

2024 6.25
2023 6.58
2022 19.38
2021 25.6
2020 24.22
2019 28.92
2018 34.42

About Checkpoint Therapeutics Financial Statements

Checkpoint Therapeutics shareholders use historical fundamental indicators, such as Graham Number, to determine how well the company is positioned to perform in the future. Although Checkpoint Therapeutics investors may analyze each financial statement separately, they are all interrelated. The changes in Checkpoint Therapeutics' assets and liabilities, for example, are also reflected in the revenues and expenses on on Checkpoint Therapeutics' income statement. Understanding these patterns can help investors time the market effectively. Please read more on our fundamental analysis page.
Last ReportedProjected for Next Year
Graham Number 6.58  6.25 

Thematic Opportunities

Explore Investment Opportunities

Build portfolios using Macroaxis predefined set of investing ideas. Many of Macroaxis investing ideas can easily outperform a given market. Ideas can also be optimized per your risk profile before portfolio origination is invoked. Macroaxis thematic optimization helps investors identify companies most likely to benefit from changes or shifts in various micro-economic or local macro-level trends. Originating optimal thematic portfolios involves aligning investors' personal views, ideas, and beliefs with their actual investments.
Explore Investing Ideas  

Additional Tools for Checkpoint Stock Analysis

When running Checkpoint Therapeutics' price analysis, check to measure Checkpoint Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Checkpoint Therapeutics is operating at the current time. Most of Checkpoint Therapeutics' value examination focuses on studying past and present price action to predict the probability of Checkpoint Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Checkpoint Therapeutics' price. Additionally, you may evaluate how the addition of Checkpoint Therapeutics to your portfolios can decrease your overall portfolio volatility.